Federal Aviation Administration

FAA Issues Statement on COVID-19-Related Drugs


posted in

April 16, 2020 – The FAA issued a statement this week on the use of chloroquine and hydroxychloroquine by airmen as a preventative measure against COVID-19 infection. Due to potential aeromedically significant side effects, the FAA has determined that medical certificate holders cannot fly while taking these medications, nor may they fly for 48 hours after discontinuing use.

If you have any questions about any medication’s impact on your medical certificate, contact your AME or EAA’s Aeromedical Services (800-564-6322 or govt@eaa.org).

On a related subject, several members have asked EAA what the aeromedical implications are of being infected with the novel coronavirus. As with any acute illness, you may resume flying upon a full recovery and in the absence of any significant complications or lingering symptoms that might affect your fitness to fly. Again, if you have any doubt, consult your AME or EAA. If you are hospitalized, you will need to note that on your next medical application but the hospitalization alone would not be disqualifying.